EP2124899A2 - Formulations pharmaceutiques stables de sel d'atorvastatine magnésium - Google Patents
Formulations pharmaceutiques stables de sel d'atorvastatine magnésiumInfo
- Publication number
- EP2124899A2 EP2124899A2 EP07849693A EP07849693A EP2124899A2 EP 2124899 A2 EP2124899 A2 EP 2124899A2 EP 07849693 A EP07849693 A EP 07849693A EP 07849693 A EP07849693 A EP 07849693A EP 2124899 A2 EP2124899 A2 EP 2124899A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- atorvastatin
- range
- pharmaceutical composition
- magnesium
- sodium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Definitions
- the present invention relates to stable pharmaceutical formulations comprising atorvastatin magnesium as the active agent.
- Atorvastatin ([R-(R*,R*)]-2-(4-fluorophenyl)- ⁇ , ⁇ -dihydroxy-5- (l-methylethyl)-3-phenyl-4- [(phenylamino)carbonyl]-lH-pyrrole-l-heptanoic acid) belongs to a well known group of drugs, statins, which are useful for the treatment of hypercholesterolemia or hyperlipidemia.
- a commercial pharmaceutical formulation of atorvastatin calcium is produced and sold by Pfizer, under te trade name Lipitor.
- Statins block the hydroxyl-methylglutaryl-coenzyme A reductase (HMG-CoA), thereby specifically inhibiting cholesterol synthesis in the liver.
- cholesterol is a vital component of all cells, it also contributes to plaque formation in arteries, which plaques increase the risk for high blood pressure, heart attack and stroke.
- Statins stabilize the plaques, making them less prone to rupturing and subsequently forming blood cloths.
- EP 247,633 discloses the synthesis of atorvastatin and its use as hypocholesterolemic agent.
- EP 409,281 discloses the synthesis of the hemi calcium salt of atorvastatin.
- Atorvastatin exists in multiple amorphous and crystalline forms. Originally, atorvastatin was synthesized in the amorphous form and most of the clinical pharmacology studies were conducted on tablets with amorphous atorvastatin hemi calcium. However, amorphous atorvastatin calcium is reported to be hydroscopic and unstable when exposed to oxygen, and it has been proven difficult to develop a stable dosage form, which does not transform into different morphological forms, discolor or even degrade.
- EP 680,320 discloses a pharmaceutical composition containing atorvastatin hemi calcium stabilized with an excipient which is a basic inorganic salt of magnesium, calcium or lithium.
- WO 2006/117761 presents crystalline and amorphous form of magnesium atorvastatin.
- X-ray diffraction (XRD) data is provided with characteristic peaks listed. Examples are provided, describing how to produce these crystal forms and also how to produce therefrom amorphous form of atorvastatin magnesium. No data for pharmaceutical formulations is provided or indications of stability.
- WO 03/068191 focuses on certain specified particle size of atorvastatin material and gives examples (see Example 4 and 5) of atorvastatin magnesium of unspecified crystal form.
- the material is non-milled, having a particle size with d go of approximately 237 ⁇ m and a d 50 of approximately 98 ⁇ m.
- the material is formulated in Opadry coated tablets comprising sodium carbonate, microcrystalline cellulose, lactose and croscarmellose sodium as main inert ingredients. These tablets are shown to have similar stability as calcium atorvastatin tablets.
- the present invention provides novel alternative pharmaceutical compositions comprising the magnesium salt of atorvastatin, i.e. hemi magnesium of atorvastatin, herein referred to as atorvastatin magnesium or atorvastatin Mg.
- atorvastatin magnesium i.e. hemi magnesium of atorvastatin
- atorvastatin Mg i.e. hemi magnesium of atorvastatin
- Pharmaceutical formulations with atorvastatin magnesium have not hitherto been indicated as being any more stable or having other advantages as compared to formulations of the more known calcium atorvastatin.
- the present inventor has tested various polymorphic forms of atorvastatin Mg and developed therefrom novel pharmaceutical formulations. These formulations are found to be very stable, and surprisingly substantially much more stable than corresponding formulations with atorvastatin hemi calcium.
- Figure 1 X-ray diffraction spectrum of atorvastatin magnesium, form B2.
- Figure 2 X-ray diffraction spectrum of atorvastatin magnesium, form B4.
- Figure 3 Stability data for pharmaceutical formulations of the invention.
- Atorvastatin Mg can be suitably prepared by conversion from another salt of atorvastatin or the closed ring lactone (Formula II), as further described in the accompanying Examples.
- the free acid or the lactone preferably the lactone
- the free acid of the compound can be prepared by hydrolysis of the lactone form of formula II or by passing the salt through a cationic exchange resin (H + resin) and evaporating the water.
- the atorvastatin Mg material in the formulation of the invention may be completely crystalline or partially crystalline, e.g. where at least 10% by weight of the material is crystalline and more preferably at least 20% of the material, more preferably at least 25%, such as at least 30 or 40% and yet more preferably at least 50% is crystalline, such as at least 60% or 75% of the material such as at least 90% of the material.
- the crystallised atorvastatin magnesium is generally of a single polymorphic form but may also comprise a mixture of two or more different polymorphs, such as, e.g., a mixture of the two polymorphs further described hereid referred to as polymorphs B2 and B4, optionally further comprising one or more further polymorphs, or a combination of either form B2 or B4 together with one or more different polymorphs of atorvastatin Mg.
- Various crystal forms of atorvastatin Mg are suitable in the formulations of the present invention. Crystalline forms of atorvastatin Mg which have been analysed are shown to exhibit characteristic X-ray diffraction (XRD) peaks and spectra.
- the formulation comprises crystalline atorvastatin Mg exhibiting one or more X-ray diffraction spectral peak selected from the values listed in Table 1 and Table 2.
- the formulation comprises crystalline atorvastatin Mg exhibiting one or more X-ray diffraction spectral peak at about 3.22, 7.61, 15.57, 18.65, 19.95, 19.95, 21.74, 22.78 and 24.00 degrees 2-theta.
- the formulations comprise crystalline atorvastatin Mg exhibiting X-ray diffraction spectral peaks at about 2.93, 8.86, 9.88, 16.44, 18.79, 20.17 and 21.65 degrees 2- theta.
- Amorphous atorvastatin Mg can also be obtained and formulations thereof are as well encompassed by the invention, as are formulations with partially crystallised atorvastatin Mg, i.e. various mixtures of crystalline and amorphous material.
- the formulations of the present invention are administered in order to deliver to the patient doses in the range from 0.5 to 500 mg per day, roughly corresponding to about 0.007 to 7.1 mg/kg of body weight for an average adult person with a body weight of 70 kg.
- the formulation of the invention comprise suitable excipients such as, but not limited to, diluents such as mannitol microcrystalline cellulose, hydrous lactose, corn starch, sucrose, silicic anhydride, or polysaccharides of the types well known in the art; binders such as methyl cellulose, carboxymethylcellulose, hydroxypropylcellulose, hydroxymethylpropylcellulose, polyvinylpyrrolidone, polyvinylalcohol, or starch; disintegrants such as crosspovidone, carboxymethylcellulose calcium, croscarmellose sodium, or starch; surfactants such as Tween 80 or polyoxyethylene-polyoxypropylene copolymer, and lubricants such as magnesium stearate, calcium stearate and stearic acid.
- suitable excipients such as, but not limited to, diluents such as mannitol microcrystalline cellulose, hydrous lactose, corn starch, sucrose, silicic
- antioxidants can also be incorporated in the formulations in order to reduce or prevent oxidation of the drug compound, they may be suitably selected from one or more of butylated hydroxyanisole (BHA), sodium ascorbate, butylated hydroxytoluene (BHT), sodium metabisulfate, malic acid, citric acid and ascorbic acid.
- BHA butylated hydroxyanisole
- BHT butylated hydroxytoluene
- sodium metabisulfate malic acid
- citric acid citric acid
- ascorbic acid sodium metabisulfate
- a stabilising alkali stabilising agent additive for example, but not limited to, one or more of the compounds sodium carbonate, sodium bicarbonate, sodium phosphate, sodium dihydrogen phosphate, disodium hydrogen phosphate disodium hydrogen orthophosphate, sodium silicate, calcium carbonate, calcium hydroxide, magnesium carbonate, magnesium hydroxide and magnesium silicate.
- Sodium carbonate is particularly preferred.
- One embodiment of the invention relates to a formulation comprising a crystallised form of atorvastatin Mg, sodium or calcium carbonate as a stabilising alkali metal additive, and preferably mannitol and microcrystalline cellulose as diluent, and other additives.
- a formulation comprising a crystallised form of atorvastatin Mg, sodium or calcium carbonate as a stabilising alkali metal additive, and preferably mannitol and microcrystalline cellulose as diluent, and other additives.
- the most preferred embodiment of the present invention relates to a formulation comprising a crystallised form of atorvastatin Mg, sodium or calcium carbonate as a stabilising alkali metal additive, and preferably mannitol and microcrystalline cellulose as diluent, and other additives.
- a formulation comprising a crystallised form of atorvastatin Mg, sodium or calcium carbonate as a stabilising alkali metal additive, and preferably mannitol and microcrystalline cellulose as diluent, and other additives.
- Another aspect of the invention provides a process for preparing stable pharmaceutical formulations of atorvastatin magnesium. It has been found that wet granulation techniques using preferably an aqueous solution, e.g. water, as a granulating liquid provides homogeneous formulations that can be formed into very stable tablets. The process is suitably employed using fully or partially crystallised material as described herein, and any of the pharmaceutical excipients described above. The wet granulation is typically performed using standard blending equipment well known to the skilled person in the pharmaceutical industry with water as the granulation medium, organic solvents such as ethanol can alse be applied and mixtures there of.
- aqueous solution e.g. water
- Atorvastatin Mg and all tablet core excipients apart from Magnesium stearate are premixed in a intensive high shear mixer. After this the blend is mixed in the high shear mixer while water is added gradually until suitable granules have formed. These granules are then typically wet sieved before being transferred to a drying apparatus.
- the drying apparatus is suitably a typical fluid bed dryer well known in the industry, other forms of drying, for example, one-pot processing, can also be applied.
- Example 2 The following table depicts the stability of atorvastatin, using various forms, formulated as described in Example 2. The samples were kept at 40 0 C, 75% relative humidity, in closed Duma bottles. Impurities as measured by HPLC.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
formulations pharmaceutiques stables comprenant de l'atorvastatine magnésium comme principe actif, de préférence sous forme cristallisée, entièrement ou partiellement. Le matériau cristallisé peut comprendre une ou plusieurs formes polymorphes, à spectres de diffraction de rayons X sur poudre caractérisés.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IS8587A IS8587A (is) | 2006-12-27 | 2006-12-27 | Atorvastatin lyfjasamsetning |
PCT/IS2007/000024 WO2008078341A2 (fr) | 2006-12-27 | 2007-12-21 | Formulations pharmaceutiques stables de sel d'atorvastatine magnésium |
Publications (1)
Publication Number | Publication Date |
---|---|
EP2124899A2 true EP2124899A2 (fr) | 2009-12-02 |
Family
ID=39473858
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP07849693A Withdrawn EP2124899A2 (fr) | 2006-12-27 | 2007-12-21 | Formulations pharmaceutiques stables de sel d'atorvastatine magnésium |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP2124899A2 (fr) |
IS (1) | IS8587A (fr) |
WO (1) | WO2008078341A2 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2130819A3 (fr) * | 2008-04-10 | 2009-12-23 | Ranbaxy Laboratories Limited | Formules cristallines de magnésium d'atorvastatine |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003245736A1 (en) * | 2002-02-14 | 2003-09-04 | Ranbaxy Laboratories Limited | Formulations of atorvastatin stabilized with alkali metal additions |
AU2005305460B2 (en) * | 2004-11-22 | 2011-04-21 | Dexcel Pharma Technologies Ltd. | Stable atorvastatin formulations |
US20080305158A1 (en) * | 2004-12-28 | 2008-12-11 | Ranbaxy Laboratories Limited | Methods For the Preparation of Stable Pharmaceutical Solid Dosage Forms of Atorvastatin and Amlodipine |
PT1879862E (pt) * | 2005-05-03 | 2011-04-19 | Ranbaxy Lab Ltd | Sais de magnésio de inibidores de hmg-coa-redutase |
US20100168201A1 (en) * | 2005-11-29 | 2010-07-01 | Biocan Limited | Polymorphs of [R-(R*, R*) ]-2-(4-Fluorophenyl)-Beta, Delta-Dihydroxy-5-(1-Methylethyl)-3-Phenyl-4-[(Phenylamino)Carbonyl]-1H-Pyrrole-1-Heptanoic Acid Magnesium Salt (2:1) |
SI22255A (sl) * | 2006-04-14 | 2007-10-31 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Novi polimorfi statinovih soli in njihova uporabav farmacevtskih formulacijah |
US20090082421A1 (en) * | 2006-05-11 | 2009-03-26 | Biocon Limited | Crystalline Form B4 of Atorvastatin Magnesium and a Process Thereof |
-
2006
- 2006-12-27 IS IS8587A patent/IS8587A/is unknown
-
2007
- 2007-12-21 EP EP07849693A patent/EP2124899A2/fr not_active Withdrawn
- 2007-12-21 WO PCT/IS2007/000024 patent/WO2008078341A2/fr active Application Filing
Non-Patent Citations (1)
Title |
---|
See references of WO2008078341A3 * |
Also Published As
Publication number | Publication date |
---|---|
IS8587A (is) | 2008-06-28 |
WO2008078341A3 (fr) | 2008-12-24 |
WO2008078341A2 (fr) | 2008-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0680320B1 (fr) | Formulation ci-981, orale, stable et son procede de preparation | |
KR100905730B1 (ko) | 약제학적 형태의 아토르바스타틴 칼슘, 이의 조성물 및아토르바스타틴 칼슘을 함유하는 약제학적 제형 | |
AT401870B (de) | Stabilisiertes pharmazeutisches mittel, enthaltend einen hmg-coa-reduktase-inhibitor wirkstoff | |
EP2063868B1 (fr) | Compositions pharmaceutiques contenant de la rosuvastatine calcique | |
HU223598B1 (hu) | (III) formájú kristályos [R-(R*,R*)]-2-(4-fluor-fenil)-béta,delta-dihidroxi-5-(1-metil-etil)-3-fenil-4-[(fenil-amino)-karbonil]-1H-pirrol-1-heptánkarbonsav- hemikalciumsó-hidrát (atorvastatin-hidrát) és a vegyületet tartalmazó gyógyászati készítmény | |
EP2229938B1 (fr) | Compositions d'ézétimibe | |
JP5412484B2 (ja) | アトルバスタチンの塩形態 | |
EP1749517B1 (fr) | Préparation pharmaceutique comprenant linezolide forme IV | |
CA2708159C (fr) | Formulation pharmaceutique comprenant de l'ezetimibe | |
AT8453U1 (de) | Kristallines (r-(r*,r*))-2-(4-fluorphenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4- ((phenylamino)carbonyl)-1h-pyrrol-1- heptancarbonsäure hemi calcium salz (atorvastatin) | |
BG108393A (bg) | Кристални форми на[r-(r*,r*)]-2-(флуорофенил)-бета, делта-дихидрокси-5-(1-метилетил)-3-фенил-4-[(фениламино)карбонил]-1н-пирол-1-хептанова киселина калциева сол (2:1) (аторвастатин) | |
WO2008020314A2 (fr) | Formulations de dosage stabilisantes à base de statine | |
US20080038332A1 (en) | Stable pharmaceutical formulation comprising atorvastatin calcium | |
WO2010098482A1 (fr) | Préparation de capsules stable et son procédé de fabrication | |
WO2008078341A2 (fr) | Formulations pharmaceutiques stables de sel d'atorvastatine magnésium | |
KR100878140B1 (ko) | 아토바스타틴의 스트론튬염 또는 이의 수화물, 및 이를포함하는 약학 조성물 | |
EP3327022A1 (fr) | Sel solide d'alpha-6-mpeg6-o-hydroxycodone comme agonistes d'opioïdes et leurs utilisations | |
EP4188338A1 (fr) | Comprimé bicouche comprenant de l'ézétimibe et de l'atorvastatine | |
US20090226515A1 (en) | Statin compositions | |
EP2117516A2 (fr) | Préparations d'atorvastatine stables | |
JP2008500327A (ja) | アトルバスタチンの塩形態 | |
EP2420488A1 (fr) | Nouvelle formule cristalline de sel hémicalcium atorvastanine, hydrate associé et son procédé de production | |
EP2779999A2 (fr) | Formulations pharmaceutiques comprenant de l'atorvastatine et du glimépiride | |
EP1532975B2 (fr) | Procédé pour la préparation d' adsorbats d'atorvastatine pulverulents à écoulement libre | |
EP1825848A2 (fr) | Compositions pharmaceutiques stables comprenant un inhibiteur de la HMG-CoA réductase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20090727 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA HR MK RS |
|
17Q | First examination report despatched |
Effective date: 20091118 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20100330 |